細胞凋亡，抗體，胜肽:藥物開發策略分析 是由出版商BioSeeker Group AB在2011年12月所出版的。
這份英文市場調查報告書包含4467 Pages 價格從美金5175起跳。
本報告以癌症治療藥開發策略上細胞凋亡的機制、目標、影響領域和抗體及胜肽的化合物領域為焦點，彙整各種的劑目標策略，化合物策略競爭基準，開發平台開發平台及最佳投資組合計劃等資料，為您概述為以下內容。
第1章 細胞凋亡
- 本報告的範圍
- 為達成最高治療效果及投資報酬率的治療目標檢討
- 新藥的上市:細胞凋亡治療開發平台上指定的藥劑目標是否成熟，是否有特色，臨床評估如何
- 使用中的化合物策略:細胞凋亡藥物的各類型化合物的競爭基準
- 細胞凋亡的癌適應症症狀選擇
- 最佳投資組合計劃:細胞凋亡開發平台的競爭基準
- 藥品目錄
- 企業目錄
- 圖表
第2章 抗體
- 本報告的範圍
- 為達成最高治療效果及投資報酬率的治療目標檢討
- 新藥的上市:癌症的抗體治療開發平台上指定的藥劑目標是否成熟，是否有特色，臨床評估如何
- 抗體治療藥物的癌適應症症狀的選擇
- 最佳投資組合計劃:癌症的抗體治療開發平台的競爭基準
- 藥品目錄
- 企業目錄
- 圖表
第3章 胜肽
- 本報告的範圍
- 胜肽治療藥物的優點與缺點
- 為達成最高治療效果及投資報酬率的治療目標檢討
- 新藥的上市:各開發階段的胜肽藥劑目標策略
- 藥物開發的癌症適應症的選擇
- 開發平台·最佳投資組合計劃:腫瘤學的胜肽開發平台的競爭基準
- 免責聲明
- 藥品目錄
- 企業目錄
- 圖表
Abstract
Product Description
This triple analysis focuses on cancer drug development strategies by the
mechanism/target/effect of Apoptosis and by the two compound strategies of
Antibodies and Peptides. Each of these three individual parts is evaluated
according to standardized criteria in a five pillar pipeline drug assessment
methodology to compare drug development strategies in oncology. This makes it
easy to find and compare analysis not only within one single cancer focus area
but also between different areas.
Below is a short synopsis of each part included in this report:
Part I: Apoptosis
The apoptosis report part comprises defined and up to date development
strategies for 171 apoptotic drugs in oncology (519 projects) within the
portfolio of 125 investigators, from Ceased to Pre-registration. This report
part extensively analyses 146 identified targets of apoptotic drugs, organized
into 120 drug target strategies, and assesses them in 53 different cancer
indications.
Part II: Antibodies
The cancer antibody drug report part comprises defined and up to date
development strategies for 531 antibody drugs in oncology within the portfolio
of 196 companies world-wide, from Ceased to Marketed. The report extensively
analyses their 255 identified drug targets, organized into 266 drug target
strategies, and assesses them in 75 cancer indications.
Part III: Peptides
The peptide report part comprises defined and up to date development
strategies for 145 cancer peptide drugs within the portfolio of 103
investigators, from Ceased to Marketed. This report part extensively analyses
125 identified targets of peptide drugs, organized into 103 drug target
strategies, and assesses them in 52 different cancer indications.
The report is written for you to understand and assess the impact of
competitor entry and corresponding changes to development strategies for your
own portfolio products. It helps teams to maximize molecule value by selecting
optimal development plans and manage risk and uncertainty. The report serves
as an external commercial advocate for pharmaceutical companies' pipeline and
portfolio planning (PPP) in cancer by:
- Providing you with competitive input to the R&D organization to guide
development of early product ideas and ensure efforts are aligned with
business objectives
- Assisting you to make informed decisions in selecting cancer indications
that are known to be appropriate for your drug' s properties
- Analyzing, correlating and integrating valuable data sources in order to
provide accurate data for valuation of pipeline, in-licensing and new business
opportunities
- Providing you with commercial analytic support for due diligence on
in-licensing and acquisition opportunities
- Supporting development of integrative molecule, pathway and disease area
strategies
- Integrating knowledge for you to consider the therapeutic target for the
highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally
to PPP and to stakeholders across your own organization. The report will also
be an important part of creating and implementing a market development plan
for cancer drugs to insure that the optimal market conditions exist by the
time the products are commercialized.
Table of Contents
Key Topics Covered:
Part I: Apoptosis
- 5.1 The Scope of this Report
- 6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and
Return on Investment (146 Drug Targets) 6
- 7 The Rise of New Products: How Mature, Unique and Clinically Validated
are the Drug Target Profiles Identified in the Cancer Apoptotic Therapeutic
Pipeline? (120 Drug Target Strategies and 171 Drugs)
- 8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Drugs
in Oncology by Compound Type (7 Different Compound Strategies)
- 9 Selecting Cancer Indications for Apoptotic Therapeutics (53 Cancer
Indications)
- 10 Portfolio Planning: Competitive Benchmarking of Apoptotic Cancer
Therapeutic Pipeline by Investigator (125 Investigators)
- 12 Drug Index
- 13 Company Index
- Figures: Includes 6 Figures
- Tables: Includes 248 Tables
- Total Number of Pages: 803
Part II: Antibodies
- 5.1 The Scope of this Report
- 6 Consider the Therapeutic Target Among Antibody Drugs in Oncology for the
Highest Therapeutic Outcome and Return on Investment (255 Drug Targets)
- 7 Emerging New Products to Established Ones: Drug Target Strategies of
Antibody Drugs in Oncology by their Highest Stage of Development (266 Drug
Targets Strategies and 531 Antibody Drugs)
- 8 Selecting Cancer Indication for Antibody Drugs (75 Cancer Indications)
- 9 Pipeline and Portfolio Planning: Competitive Benchmarking of the
Antibody Drug Pipeline in Oncology by Investigator (196 Investigators and 531
Antibody Drugs)
- 10 Disclaimer
- 11 Drug Index
- 12 Company Index
- Figures: Includes 5 Figures
- Tables: Includes 347 Tables
- Total Number of Pages: 1,944
Part III: Peptides
- 5.1 The Scope of this Report
- 5.2 The Competitive Advantage and Disadvantage of Peptide Drugs
- 6 Consider the Therapeutic Peptide Target for the Highest Therapeutic
Outcome and Return on Investment (125 Drug Targets)
- 7 Emerging New Products to Established Ones: Drug Target Strategies of
Peptides by their Highest Stage of Development in Oncology (103 Drug Target
Strategies and 145 Peptide Drugs)
- 8 Selecting Cancer Indications for Peptide Drugs (52 Cancer Indications)
- 9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Peptide
Drug Pipeline in Oncology by Investigator (103 Investigators)
- 10 Disclaimer
- 11 Drug Index
- 12 Company Index
- Figures: Includes 4 Figures
- Tables: Includes 192 Tables
- Total Number of Pages: 596
Featured Compnaies
This Report Includes the Following Companies:
- A&G Pharmaceutical
- Abbott
- Abiogen
- Ablynx
- AC Immune
- Acceleron Pharma
- Access
- Actinium Pharmaceuticals
- Active Biotech
- Adherex
- Advanced Life Sciences
- AEgera
- AEterna Zentaris
- Affibody
- Affimed Therapeutics
- Affitech
- AGY Therapeutics
- Aida Pharmaceuticals
- Alder Biopharmaceuticals
- Alethia Biotherapeutics
- Alexion
- Alfacell
- Algeta
- ALSP
- Altor BioScience
- Ambrilia Biopharma
- Amgen
- Amorfix Life Sciences
- Anavex Life Sciences
- AngioChem
- Angstrom Pharmaceuticals
- Antisoma
- Aphios
- ApopLogic Pharmaceuticals
- Apricus Biosciences
- Apthera
- Arana Therapeutics
- Arca biopharma
- arGEN-X
- Arno Therapeutics
- ArQule
- Ascenta Therapeutics
- Astellas
- AstraZeneca
- Attenuon
- Avaxia
- AVEO
- AVI BioPharma
- Bayer
- Berkeley Lab
- BioAlliance Pharma
- BioAxone
- Biocon
- Biogen Idec
- BioInvent
- Biokine Therapeutics
- Biolex
- BioLineRx
- Bionovo
- Biosceptre
- Biotecnol
- Biotest
- BioVex
- Boehringer Ingelheim
- Bristol-Myers Squibb
- BTG
- CanBas
- Cancer Innovations
- Cancer Research Technology
- CDG Therapeutics
- Celecure
- Celldex Therapeutics
- Celltrion
- Celtic Pharma
- Center of Molecular Immunology
- Cephalon
- CG Therapeutics
- ChemoCentryx
- Chemokine Therapeutics
- Circadian Technologies
- Coronado Biosciences
- Critical Outcome Technologies
- CSL
- CuraGen
- CureTech
- Curis
- Cyclacel
- Cylene Pharmaceuticals
- CytImmune Sciences
- Cytochroma
- Daewoong
- Daiichi Sankyo
- Dainippon Sumitomo Pharma
- Dendreon
- DiaMedica
- Dompe
- Dr Reddy' s
- Dyax
- Eisai
- Elan
- Eleos
- Eli Lilly
- Emergent BioSolutions
- Enkam Pharmaceuticals
- EntreMed
- Enzon
- EpiCept
- Epitomics
- Esperance Pharmaceuticals
- EUSA Pharma
- Exelixis
- Faron Pharmaceuticals
- Favrille
- Femta Pharmaceuticals
- FibroGen
- Five Prime Therapeutics
- Fusion Antibodies
- Galaxy Biotech
- GammaCan
- Ganymed Pharmaceuticals
- Gene Techno Science
- Genencor
- Genentech
- Generex
- Genmab
- Genomic Systems
- GenPat77
- Genta
- Genzyme
- Geron
- Gilead Sciences
- GlaxoSmithKline
- Gliknik
- GlycoGenesys
- Glycotope
- Green Cross
- Hawthorn Pharmaceuticals
- Hoffmann-La Roche
- Human Genome Sciences
- Idera Pharmaceuticals
- IDM Pharma
- ImClone Systems
- IMED
- Immune Pharmaceuticals
- ImmunoCellular Therapeutics
- ImmunoGen
- Immunomedics
- Immunotope
- ImmuPharma
- Immutep
- Infinity Pharmaceuticals
- Innate Pharma
- InNexus Biotechnology
- Innovive
- Insmed
- Intracel
- Intradigm
- Introgen Therapeutics
- ISA Pharmaceuticals
- Isis Pharmaceuticals
- ISU ABXIS
- Johnson & Johnson
- Kaketsuken
- KaloBios
- Kalypsys
- Karyon-CTT
- Kirin Pharma
- Kissei
- Kyowa Hakko Kirin
- Kyto Biopharma
- Lee' s Pharmaceutical
- LFB Biotechnologies
- LG Life Sciences
- Lorus Therapeutics
- MacroGenics
- Mannkind
- Marillion Pharmaceuticals
- MAT Biopharma
- Medarex
- MediGene
- MedImmune
- Mediolanum
- Medisyn Technologies
- Menarini
- Merck & Co
- Merck KGaA
- Merrimack
- MethylGene
- Micromet
- Mitsubishi Tanabe Pharma
- MolMed
- Mycenax
- Nektar Therapeutics
- Nemod Biotherapeutics
- NeoPharm
- Neovacs
- Neuren
- Nidus Laboratories
- NIH
- Nippon Shinyaku
- NKT Therapeutics
- Non-industrial source
- Northwest Biotherapeutics
- Novacea
- Novartis
- Novelix
- Novogen
- OncoMed
- Onconova
- OncoTherapy Science
- Oncothyreon
- Onyvax
- OSI Pharmaceuticals
- Oxford BioMedica
- OXiGENE
- Paladin Labs
- Panacea
- PanaGin
- PanGenetics
- Patrys
- Pepscan Therapeutics
- PepTx
- Peregrine Pharmaceuticals
- Perseus Proteomics
- Pfizer
- Pharmacyclics
- PharmaGap
- PharmaMar
- Pharmexa
- Pharminox
- Philogen
- Pierre Fabre
- Prima Biomed
- ProCell Therapeutics
- Prochon Biotech
- Progenics Pharmaceuticals
- Ramot
- Raptor Pharmaceutical
- Reata Pharmaceuticals
- Recepta biopharma
- Receptor BioLogix
- Regeneron
- Regulon
- Sanofi-Aventis
- Santaris Pharma
- SBI Biotech
- Scancell
- SciClone Pharmaceuticals
- Seattle Genetics
- Semafore Pharmaceuticals
- Shenogen
- Shire
- Sigma-Tau
- SRI International
- Stainwei Biotech
- Sunol Molecular
- SuperGen
- SuppreMol
- Switch Pharma
- Symbiotec
- Symphogen
- Synageva BioPharma
- SynerGene Therapeutics
- Takeda
- Targa Therapeutics
- Taxolog
- TeGenero
- Telik
- Teva
- Thallion Pharmaceuticals
- Therapure Biopharma
- Therion Biologics
- Theryte
- ThromboGenics
- Tigris Pharmaceuticals
- Titan Pharmaceuticals
- Tolerx
- TopoTarget
- Tracon Pharmaceuticals
- Transgene
- Trillium Therapeutics
- Trion Pharma
- UCB
- United Biomedical
- United Therapeutics
- Vaccinex
- Wakunaga
- Vascular Biogenics
- VasGene Therapeutics
- Vaxil BioTherapeutics
- Vaxon Biotech
- VaxOnco
- Vertex Pharmaceuticals
- Vical
- Wilex
- VioQuest
- Viragen
- Viralytics
- ViroTarg
- Viventia Biotech
- XBiotech
- Xencor
- Xerion
- Xoma
- Y' s Therapeutics
- YM BioSciences
- Zenotech
- Zensun
- ZymoGenetics
Featured Drugs
A Shortlist of Drugs Included are:
- 131I-tositumomab
- 2-methoxyestradiol
- A6
- abagovomab
- abarelix
- ABT-263
- ABT-510
- AEG-35156
- AEZS-108
- aflibercept
- afutuzumab
- alemtuzumab
- alvocidib
- AMG-386
- angiopep+paclitaxel
- Apomab
- ARQ-197
- AS-1411
- atiprimod dimaleate
- ATN-224
- belinostat
- bevacizumab
- brentuximab vedotin
- BZL-101
- canfosfamide hydrochloride
- catumaxomab
- CBLC-102
- CBP-501
- cenersen
- cetrorelix acetate
- cetuximab
- cintredekin besudotox
- combretastatin A-4 prodrug
- conatumumab
- CS-1008
- denosumab
- deslorelin
- dulanermin
- E-75
- farletuzumab
- galiximab
- GCS-100LE
- gemtuzumab ozogamicin
- girentuximab
- GRN-163L
- GV-1001
- HE-3235
- Her-2/Neu peptides
- histrelin
- ibritumomab tiuxetan
- idronoxil
- indisulam
- INGN-241
- INGN-401
- inotuzumab ozogamicin
- ipilimumab
- ISA-P53-01
- ISIS-23722
- kahalalide F
- leuprolide
- leuprorelin
- lonaprisan
- lumiliximab
- mapatumumab
- MGCD-0103
- MKC-1
- MKC-1106-MT
- motexafin gadolinium
- naptumomab estafenatox
- necitumumab
- netupitant
- NGR-TNF
- nimotuzumab
- obinutuzumab
- oblimersen sodium
- ofatumumab
- oregovomab
- OTS-102
- ozarelix
- panitumumab
- panobinostat
- PARP inhibitors
- pasireotide
- PAT-SC1
- patupilone
- PCI-24781
- PEP-223
- pertuzumab
- plitidepsin
- quarfloxacin
- ramucirumab
- Reditux
- retaspimycin
- Rh-Apo2L
- rindopepimut
- rituximab
- romiplostim
- romurtide
- sagopilone
- seliciclib
- sotatercept
- Stimuvax
- thymalfasin
- tigapotide triflutate
- TLN-232
- trastuzumab
- triciribine
- TRU-016
- voreloxin
- VX-001
- VX-944
- XL-647
- zalutumumab
- zanolimumab
